相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Understanding and Managing Corticosteroid-Induced Osteoporosis
Alexandra O. Kobza et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2021)
Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study
Ikuko Tanaka et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2021)
Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
Yasuaki Hirooka et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
H. Hagino et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Fracture Risk and Its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study
Bora Nam et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2021)
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho et al.
ENDOCRINOLOGY AND METABOLISM (2021)
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Pojchong Chotiyarnwong et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Trends in long-term glucocorticoid use and risk of 5-year mortality: a historical cohort study in South Korea
Tak Kyu Oh et al.
ENDOCRINE (2020)
Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark
Kristina Laugesen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)
Nicola Napoli et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy
Rowan S. Hardy et al.
ENDOCRINE REVIEWS (2018)
Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis
Dam Kim et al.
JOURNAL OF RHEUMATOLOGY (2018)
Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France
Anne Benard-Laribiere et al.
BMJ OPEN (2017)
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Lenore Buckley et al.
ARTHRITIS & RHEUMATOLOGY (2017)
24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitsugu Sugimoto et al.
ADVANCES IN THERAPY (2017)
Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide
Roger Zebaze et al.
BONE (2017)
Teriparatide for osteoporosis: importance of the full course
R. Lindsay et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
Takahiro Seno et al.
SPRINGERPLUS (2016)
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study
S. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide
Shiro Tanaka et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Yasuo Suzuki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
T. Sugimoto et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Prevalence of oral glucocorticoid usage in the United States: A general population perspective
Robert A. Overman et al.
ARTHRITIS CARE & RESEARCH (2013)
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases
Akimitsu Miyauchi et al.
BONE (2010)
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
Barbara M. Obermayer-Pietsch et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
B Ettinger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
JR Zanchetta et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
分享论文
